Browse
related articles
The event was also attended by Peter Harradine, President of Swiss Business Council, and representatives of the major biotechnology companies at the life sciences cluster in Dubai.
In addition to collaboration between the two biotechnology organisations, one of the initiatives under the agreement includes a campaign to raise awareness among the Swiss biotechnology and medical technology companies about the Middle East's growing healthcare market and the benefits offered by DuBiotech as a life sciences free zone.
Dr Marco Baccanti, Executive Director, DuBiotech, said:
"Considering the strategic importance and the technology advancement of the Swiss biotechnology and medical technology sectors, and the benefits the DuBiotech platform offers to these industries, the agreement is an ideal move to ensure mutual advantages to the UAE and Swiss biotechnology companies."
Domenico P. Alexakis, CEO of Swiss Biotech Association, said, "We are actively supporting all our 183 members to develop their business opportunities. With the collaboration between DuBiotech and the national industry association, the awareness level will increase and generate additional value for the industry."
The Swiss Biotech Association's members are well connected to a cluster of 400 Swiss medical technology companies. The association will offer all these companies an opportunity to participate in seminars in the Middle East that will be co-organised by DuBiotech and the Swiss Biotech Association.
Currently, DuBiotech hosts some of the world's top pharmaceutical/biotechnology companies such as Pfizer, Genzyme and Merck Serono, and has firmly established itself as a globally recognised centre for the life science industries.
Digg
Facebook
LinkedIn
Twitter
Posted by Siba Sami Ammari
It looks like you are using a Mac - check out our 
Web Feeds